Literature DB >> 22015296

Breast cancer and microRNAs: therapeutic impact.

Marilena V Iorio1, Patrizia Casalini, Claudia Piovan, Luca Braccioli, Elda Tagliabue.   

Abstract

Despite advances in detection and therapies, breast cancer is still the leading cause of cancer death in women worldwide. The etiology of this neoplasm is complex, and both genetic and environmental factors contribute to the complicate scenario. Gene profiling studies have been extensively used over the last decades as a powerful tool to define the signature of different cancers and to predict outcome and response to therapies. More recently, a new class of small (19-25 nucleotides) non-coding RNAs, microRNAs (miRs or miRNAs) has been linked to several human diseases, included cancer. MicroRNAs are involved in temporal and tissue-specific eukaryotic gene regulation,(1) either by translational inhibition or exonucleolytic mRNA decay, targeted through imperfect complementarity between the microRNA and the 3' untranslated region (3'UTR) of the mRNA.(2) Since their ability to potentially target any human mRNA, it is likely that microRNAs are involved in almost every biological process, including cell cycle regulation, cell growth, apoptosis, cell differentiation and stress response.(3) The involvement of microRNAs in the biology of human cancer is supported by an increasing body of experimental evidence, that has gradually switched from profiling studies, as the first breast cancer specific signature reported in 2005 by our group(4) describing an aberrant microRNA expression in different tumor types, to biological demonstrations of the causal role of these small molecules in the tumorigenic process, and the possible implications as biomarkers or therapeutic tools.(5) These more recent studies have widely demonstrated that microRNAs can modulate oncogenic or tumor suppressor pathways, and that, at the same time, their expression can be regulated by oncogenes or tumor suppressor genes. The possibility to modulate microRNA expression both in vitro and in vivo by developing synthetic pre-microRNA molecules or antisense oligonucletides has at the same time provided a powerful tool to a deeper comprehension of the molecular mechanisms regulated by these molecules, and suggested the intriguing and promising perspective of a possible use in therapy. Here we review our current knowledge about the involvement of microRNAs in cancer, focusing particularly on breast cancer, and their potential as diagnostic, prognostic and therapeutic tools.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015296     DOI: 10.1016/S0960-9776(11)70297-1

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  40 in total

1.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

2.  Positive expression of miR-361-5p indicates better prognosis for breast cancer patients.

Authors:  Zhi-Gang Cao; Yan-Ni Huang; Ling Yao; Yi-Rong Liu; Xin Hu; Yi-Feng Hou; Zhi-Min Shao
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 3.  Linking epithelial-to-mesenchymal-transition and epigenetic modifications.

Authors:  Sonja C Stadler; C David Allis
Journal:  Semin Cancer Biol       Date:  2012-06-15       Impact factor: 15.707

4.  Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.

Authors:  R Gan; Y Yang; X Yang; L Zhao; J Lu; Q H Meng
Journal:  Cancer Gene Ther       Date:  2014-06-13       Impact factor: 5.987

Review 5.  miRNAs and estrogen action.

Authors:  Carolyn M Klinge
Journal:  Trends Endocrinol Metab       Date:  2012-04-11       Impact factor: 12.015

Review 6.  Tumour-derived miRNAs and bone metastasis.

Authors:  Martine Croset; Casina Kan; Philippe Clézardin
Journal:  Bonekey Rep       Date:  2015-05-13

Review 7.  Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis.

Authors:  Shichao Li; Xiaorong Yang; Jinmei Yang; Jiesheng Zhen; Dechun Zhang
Journal:  Clin Exp Med       Date:  2014-12-17       Impact factor: 3.984

8.  miR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3.

Authors:  Yunyun Li; Zhongzu Zhang; Xiuxia Liu; Tingting Huang; Wenfeng He; Yang Shen; Xin Liu; Kui Hong; Qing Cao
Journal:  Mol Cell Biochem       Date:  2013-11-28       Impact factor: 3.396

9.  miR-221/222 control luminal breast cancer tumor progression by regulating different targets.

Authors:  Patrizia Dentelli; Matteo Traversa; Arturo Rosso; Gabriele Togliatto; Cristina Olgasi; Caterina Marchiò; Paolo Provero; Antonio Lembo; Giulia Bon; Laura Annaratone; Anna Sapino; Rita Falcioni; Maria Felice Brizzi
Journal:  Cell Cycle       Date:  2014-04-15       Impact factor: 4.534

10.  Let-7a functions as a tumor suppressor in Ewing's sarcoma cell lines partly by targeting cyclin-dependent kinase 6.

Authors:  Zhongzu Zhang; Lu Huang; Zhiming Yu; Xiang Chen; Dong Yang; Ping Zhan; Min Dai; Shanhu Huang; Zhimin Han; Kai Cao
Journal:  DNA Cell Biol       Date:  2014-01-02       Impact factor: 3.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.